Deep Track Biotechnology Master Fund, Ltd. - 12 Sep 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC

Role
10%+ Owner
Signature
Deep Track Biotechology Master Fund, Ltd. /s/ David Kroin, Director
Issuer symbol
LBRX on Nasdaq
Transactions as of
12 Sep 2025
Net transactions value
+$39,999,990
Form type
4
Filing time
16 Sep 2025, 18:09:13 UTC
Previous filing
10 Sep 2025
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (3)

Name Relationship Address Signature Signature date CIK
Deep Track Biotechnology Master Fund, Ltd. 10%+ Owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVE, GEORGE TOWN, CAYMAN ISLANDS Deep Track Biotechology Master Fund, Ltd. /s/ David Kroin, Director 16 Sep 2025 0002015536
Deep Track Capital, LP 10%+ Owner 200 GREENWICH AVE, 3RD FLOOR, GREENWICH Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser 16 Sep 2025 0001856083
KROIN DAVID 10%+ Owner C/O DEEP TRACK CAPITAL, LP, 200 GREENWICH AVE, 3RD FLOOR, GREENWICH /s/ David Kroin 16 Sep 2025 0001397513

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LBRX Common Stock Conversion of derivative security +686,138 686,138 12 Sep 2025 Direct F1, F2
transaction LBRX Common Stock Purchase $30,000,000 +2,000,000 +291% $15.00 2,686,138 12 Sep 2025 Direct F2
transaction LBRX Common Stock Purchase $9,999,990 +666,666 $15.00 666,666 12 Sep 2025 By Deep Track Special Opportunities Fund, LP F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LBRX Series C Preferred Stock Conversion of derivative security -16,666,667 -100% 0 12 Sep 2025 Common Stock 686,138 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.
F2 Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.
F3 Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.